Nine patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2040. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2040
Next term end
5
Patent families
When these terms end
Each bar runs from grant to computed term end. 2021 to 2042.
US 11,590,107
METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS
no later than Dec 3, 2040
US 12,616,667
Compositions and Methods for Improving Neurological Diseases and Disorders
no later than Nov 14, 2042
202520292033203720412042
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
14 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2040 · High confidence
Also notable
Ends Apr 2041 · High confidence
Also notable
Ends no later than Dec 2040 · Medium confidence
Beta Adrenergic Agonist and Methods of Using the Same
US 11,040,944
A family of 9 related applications built on the 2021 grant. Protection runs to 2040.
Methods for Improving Neurological Diseases and Disorders
US 11,607,395
A family of 5 related applications built on the 2023 grant. Protection runs to 2041.
METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS
US 11,590,107
The newest of the three, granted 2023. It anchors the portfolio to 2040, later than anything else here. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
- 2 of the patents on this record were granted since Aug 20, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Beta Adrenergic Agonist and Methods of Using the Same | 4 in force | to Sep 2040 |
| Methods for Improving Neurological Diseases and Disorders | 2 in force | to Apr 2041 |
| ALPHA1A-ADRENERGIC Receptor Agonists and Methods of Use | 1 in force | to Dec 2042 |
| Compositions and Methods for Improving Neurological Diseases and Disorders | 1 in force | to Nov 2042 |
| METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS | 1 in force | to Dec 2040 |
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,947,196 | Beta Adrenergic Agonist and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 11,040,944 | Beta Adrenergic Agonist and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 12,448,352 | Beta Adrenergic Agonist and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 12,790,299 | Beta Adrenergic Agonist and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 11,590,107 | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTS In force · Medium confidence | In force | Medium confidence | |
| US 11,607,395 | Methods for Improving Neurological Diseases and Disorders In force · High confidence | In force | High confidence | |
| US 12,558,325 | Methods for Improving Neurological Diseases and Disorders In force · High confidence | In force | High confidence | |
| US 12,616,667 | Compositions and Methods for Improving Neurological Diseases and Disorders In force · Medium confidence | In force | Medium confidence | |
| US 12,723,038 | ALPHA1A-ADRENERGIC Receptor Agonists and Methods of Use In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 14 applications pending · 7 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed